To assess the effect of c-Src on resistin-induced invasion, we pre-treated breast cancer cells with the c-Src inhibitor PP2, and analyzed the invasion ability of MDA-MB-231 cells via a transwell assay. The gene discussed is RETN; the disease is breast cancer.